ID: ALA114427

Max Phase: Preclinical

Molecular Formula: C25H33N3O4S

Molecular Weight: 471.62

Molecule Type: Small molecule

Representations

Synonyms (1): GW9471
Synonyms from Alternative Forms(1):

Canonical SMILES:  CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1ccccc1)C(=O)NO

Standard InChI:  InChI=1S/C25H33N3O4S/c1-17(2)14-20(21(24(30)28-32)16-33-19-12-8-5-9-13-19)23(29)27-22(25(31)26-3)15-18-10-6-4-7-11-18/h4-13,17,20-22,32H,14-16H2,1-3H3,(H,26,31)(H,27,29)(H,28,30)/t20-,21+,22+/m1/s1

Standard InChI Key:  UBFGIEDUTRCMEQ-FSSWDIPSSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 471.62

Molecular Weight (Monoisotopic): 471.2192

AlogP: 3.04

#Rotatable Bonds: 12

Polar Surface Area: 107.53

Molecular Species: NEUTRAL

HBA: 5

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.86

CX Basic pKa:

CX LogP: 3.33

CX LogD: 3.31

Aromatic Rings: 2

Heavy Atoms: 33

QED Weighted: 0.22

Np Likeness Score: -0.26

References

1. Bailey S, Bolognese B, Buckle DR, Faller A, Jackson S, Louis-Flamberg P, McCord M, Mayer RJ, Marshall LA, Smith DG..  (1998)  Selective inhibition of low affinity IgE receptor (CD23) processing.,  8  (1): [PMID:9871623] [10.1016/s0960-894x(97)10149-4]

2. Barlaam B, Bird TG, Lambert-Van Der Brempt C, Campbell D, Foster SJ, Maciewicz R..  (1999)  New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.,  42  (23): [PMID:10579851] [10.1021/jm990377j]

3. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data